Enhancement of Hybridoma Formation

  • Arie H. Bartal
  • Yashar Hirshaut
Part of the Contemporary Biomedicine book series (CB, volume 7)

Abstract

Efforts to enhance cell fusion technologies can be traced back to the earliest cell fusion attempts. In vitro cell fusion was first described by Lambert, who reported in 1912 the formation of large polykaryons from cultured macrophages treated with lycopodium spores (1). In subsequent years, the appearance of multinucleated cells following spontaneous in vitro cell fusion was sporadically described (2–4), all involving cells of the same lineage.

Keywords

DMSO Tuberculosis Selenium Dexamethasone Estradiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lambert R. A.: 1912. The production of foreign body giant cells in vitro. J. Exp. Med. 15: 510–515.PubMedCrossRefGoogle Scholar
  2. 2.
    Lewis W. H.: 1927. The formation of giant cells in tissue culture and their similarity to those in tuberculosis lesion. Am. Rev. Tuberc. 15: 616–628.Google Scholar
  3. 3.
    Harris H.: 1970. Cell Fusion. The Dunham Lectures. Oxford University Press. London and New York.Google Scholar
  4. 4.
    Ringertz N. R. and Savage R. E.: 1976. Cell Hybrids. Academic, New York.Google Scholar
  5. 5.
    Barski G., Sorieul S., and Cornefert F.: 1960. Production dans des cultures in vitro de deux souches cellulaires en association de cellules de caractere ‘hybride’. Compt. Rend. Acad. Sc. 251: 1825–1827.Google Scholar
  6. 6.
    Barski G., Sorieul S., and Cornefert F.: 1961. ‘Hybrid’ type cells in combined cultures of two different mammalian cell strains. J. Natl. Cancer Inst. 26: 1269–1291.PubMedGoogle Scholar
  7. 7.
    Barski G., Belehradek J. Jr.: 1979. Inheritance of malignancy in somatic cell hybridomas. Som. Cell Genet. 5: 897–908.CrossRefGoogle Scholar
  8. 8.
    Gershon D. and Sachs L.: 1963. Properties of a somatic hybrid between mouse cells with different genotypes. Nature 198: 912–914.PubMedCrossRefGoogle Scholar
  9. 9.
    Ephrussi B. and Weiss M. C.: 1965. Interspecific hybridization of somatic cells. Proc. Natl. Acad. Sci. USA 53: 1040–1042.PubMedCrossRefGoogle Scholar
  10. 10.
    Huppert J.: 1983. Somatic cell hybrids. Follia Biologica (Praha) 29: 56–64.Google Scholar
  11. 11.
    Enders J. F. and Peebles T. C.: 1954. Propagation in tissue culture of cytopathogcnic agents from patients with measles. Proc. Soc. Expt. Biol. Med. 86: 227–286.Google Scholar
  12. 12.
    Okada Y.: 1958. The fusion of Ehrlich’s tumor cells caused by HYJ virus in vitro. Biken’s J. 1: 103–110.Google Scholar
  13. 13.
    Okada Y. and Tadokoro J.: 1962. Analysis of giant polynuclear cell formation caused by HJV virus from Ehrlich’s tumor cells. II. Quantative analysis of giant polynuclear cell formation. Exp. Cell Res. 26: 108–118.PubMedCrossRefGoogle Scholar
  14. 14.
    Harris H. and Watkins J. F.: 1965. Hybrid cells derived from mouse and man: Artificial heterokaryons of mammalian cells from different species. Nature (Lond.) 205: 640–646.PubMedCrossRefGoogle Scholar
  15. 15.
    Lucy J. A.: 1970. The fusion of biological membranes. Nature (Lond.) 227: 815–817.PubMedCrossRefGoogle Scholar
  16. 16.
    Kohler G. and Milstein C.: 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497.PubMedCrossRefGoogle Scholar
  17. 17.
    Kao K. N. and Michayluk M. R.: 1974. A method for high-frequency interegeneric fusion of plant protoplasts. Planta 115: 355–367.CrossRefGoogle Scholar
  18. 18.
    Pontecorvo G.: 1975. Production of indefinitely multiplying mammalian somatic cell hybrids by polyethylene glycol (PEG) treatment. Somat. Cell Genet. 1: 397–400.PubMedCrossRefGoogle Scholar
  19. 19.
    Galfre G., Howe S. C„ Milstein C., Butcher G. W„ and Howard J. C: 1977. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 266: 550–552.PubMedCrossRefGoogle Scholar
  20. 20.
    Galfre G. and Milstein C.: 1981. Preparation of monoclonal antibodies: strategies and procedures. Meth. Enzymol. 73: 1–46.Google Scholar
  21. 21.
    Chang T. H., Steplewski Z., and Koprowski H.: 1980. Production of monoclonal antibodies in serum free medium. J. Immunol. Meth. 39: 369–375.CrossRefGoogle Scholar
  22. 22.
    Kovar J. and Franek F.: 1984. Serum free medium for hybridoma and parental myeloma cell cultivation: A novel composition of growth supporting substances. Immunol. Lett. 7: 339–345.PubMedCrossRefGoogle Scholar
  23. 23.
    Taggart R. T. and Samloff I. M.: 1983. Stable antibody-producing murine hybridomas. Science 219: 1128–1230.CrossRefGoogle Scholar
  24. 24.
    Miyahara M., Nakamura H., and Hamaguchi Y.: 1984. Colcemid treatment of myeloma prior to cell fusion increases the yield of hybridomas between myeloma and splenocyte. Biochem. Biophys. Res. Comm. 124: 903–908.PubMedCrossRefGoogle Scholar
  25. 25.
    Siraganian R. P., Fox, P. C., and Berenstein E. H.: 1981. Methods of enhancing the frequency of antigen-specific hybridomas. Meth. Enzymol. 92: 17–26.CrossRefGoogle Scholar
  26. 26.
    Gefter M. L., Margulies D. H., and Scharff M. D.: 1977. A simple method for polyethylene glycol promoted hybridization of mouse myeloma cells. Somat. Cell Genet. 3: 231–236.PubMedCrossRefGoogle Scholar
  27. 27.
    Eshhar Z., Ofarim M., and WaksT.: 1980. Generation of hybridomas secreting murine reaginic antibodies of anti-DNP specificity. J. Immunol. 124: 775–780.PubMedGoogle Scholar
  28. 28.
    Stahli C., Staehelin Th., Miggiano Y., Schmidt J., and Haring P.: 1980. High frequencies of antigen specific hybridomas: Dependence on immunization parameters and prediction by spleen ceil analysis. J. Immunol. Meth. 32: 297–304.CrossRefGoogle Scholar
  29. 29.
    Claflin L. and Williams K.: 1978. Mouse-Myeloma Spleen Cell Hybrids: Enhanced Hybridizations Frequencies and Rapid Screening Procedures, in Lymphocyte.Melanomas ( F. Melcher, M. Potter, N. Warner, eds.) Springer Yerlag, Berlin, New York.Google Scholar
  30. 30.
    Norwood T. H., Zeigler C.J., and Martin G. M.: 1976. Dimethyl sulfoxide enhances polyethylene glycol-mediated somatic cell fusion. Somat. Cell Gen. 2: 263–270.CrossRefGoogle Scholar
  31. 31.
    Mercer W. E. and Schlegel R. A.: 1979. Phytohemagglutinin enhancement of cell fusion reduces polyethylene glycol cytotoxicity. Exp. Cell Res. 120: 417–421.PubMedCrossRefGoogle Scholar
  32. 32.
    Bartal A. H., Feit C., and Hirshaut Y.: 1986. Modulation of hybridoma formation by dexamethasone. Natural immunity. Cell Growth Regul. 5: 107–112.Google Scholar
  33. 33.
    Bartal A. H., Feit C, and Hirshaut Y.: 1984. The addition of insulin to HAT medium (HIAT) enhances hybridoma formation. Devel. Biol. Standard. 57: 27–33.Google Scholar
  34. 34.
    Feit C., Bartal A. H., and Hirshaut Y.: 1984. Enhancement of hybridoma formation by addition of insulin to HAT medium (HIAT). Hybridoma 3: 377–380.PubMedCrossRefGoogle Scholar
  35. 35.
    Bartal A. H., Feit C., and Hirshaut Y.: 1986. The use of insulin enriched culture medium and human-human hybridoma formation. A preliminary study. Acta Hematol. 76: 50–53.CrossRefGoogle Scholar
  36. 36.
    Astaldi G. C. B., Janssen M. C., Lansdorp P., Willems C., Zeijlmaker W. P., and Oosterhof F.: 1980. Human endothelial culture supernatant (HECS): A growth factor for hybridomas. J. Immunol. 125: 1411–1414.PubMedGoogle Scholar
  37. 37.
    Astaldi G. C. B., Janssen M. C, Lansdorp P. M„ Zeijlemaker W. P., and Willemis C.: 1981. Human endothelial culture supernatant (HECS): Eyidence for a growth promoting factor binding to hybridoma and myeloma cells. J. Immunol. 126: 1170–1173.PubMedGoogle Scholar
  38. 38.
    Astaldi G. C. B.: 1983. Use of human endothelial culture supernatant (HECS) as a growth factor for hybridomas. Meth. Enzymol. 92: 39–47.PubMedCrossRefGoogle Scholar
  39. 39.
    Murikami H., Masui H., Sato G. H., Sueska N., Chan T. P., and Kano Sueska T.: 1982. Growth of hybridoma cells in scrum free medium: Ethamolamine is an essential component. Proc. Natl. Acad. Sci. USA 79: 1158–1162.CrossRefGoogle Scholar
  40. 40.
    Fazekas de St. Groth S. and Scheigger D.: 1985. Production of monoclonal antibodies: Strategy and tactics. J. Immunol. Meth. 35: 1–21.Google Scholar
  41. 41.
    W’esterwoudt R. J.: 1985. Improved fusion method. IV. Technical aspects. J. Immunol. Meth. 77: 181–196.CrossRefGoogle Scholar
  42. 42.
    Bartal A. H. and Hirshaut Y.: 1987. Current Methodologies in Hybridoma Formation, in Methods in Hybridoma Formation ( A. H. Bartal and Y. Hirshaut, eds.) Humana, New Jersey.Google Scholar

Copyright information

© The Humana Press Inc. 1987

Authors and Affiliations

  • Arie H. Bartal
  • Yashar Hirshaut

There are no affiliations available

Personalised recommendations